Nurix Therapeutics Shares Plunge 28.4% as Sanofi Terminates STAT6 Drug Development Programme

Sanofi halted development of SAR448272, an immune disease drug licensed from Nurix, due to nonclinical findings. Nurix received a $10M payment earlier and shares dropped over 40%. Sanofi still sees potential in the STAT6 pathway but not this specific molecule. Nurix and Sanofi partnered in 2020 with a potential $2.5B deal.

Nurix Therapeutics (NRIX) shares fell after Sanofi (SNY) ended development of their joint eczema drug, SAR448272/NX-3911, due to nonclinical findings. Analyst David Risinger of Leerink Partners cited Sanofi's statement. The decision impacted Nurix's stock price.

Nurix Therapeutics (NRXX) fell after Sanofi ended studies on an inflammatory disease drug, SAR448272, in Phase 1 trials. Nurix will not receive milestone payments or royalties. The company has $1.1B in cash and reaffirmed its runway guidance into H2 2029.

Nurix Therapeutics (NRIX) stock fell 28.4% after Sanofi terminated a Phase 1 clinical trial for SAR448272, ending future milestone payments and royalties. Jefferies cut its price target from $45 to $36. Nurix has $1.1B in cash to fund operations until 2029, and other collaborations remain active.

Nurix Therapeutics (NRIX) shares dropped 35% after Sanofi ended a Phase 1 study of an oral drug licensed from Nurix. The drug, SAR448272, was for inflammatory and autoimmune conditions. Nurix stands to lose $455M in potential milestones and royalties but retains other partnerships and $1.1B in cash. The company's other programs, including bexobrutinib in Phase 3, remain in development.

Sanofi ended a Phase 1 trial of STAT6 degrader SAR448272 and terminated the program, per a Nov. 3, 2026, notice to Nurix Therapeutics. Nurix remains eligible for milestone payments and royalties from other licensed programs under the Sanofi collaboration. Analysts have a Buy rating and $35.00 price target for NRIX, while Spark's AI Analyst rates it Neutral.